LEXICON
No.41 January 31, 2011

System for the relief of victims of adverse drug reactions
副作用被害救済制度

Based on the Pharmaceuticals and Medical Devices Agency Act (医薬品医療機器総合機構法), a package of benefits is provided to victims of health problems due to adverse drug reactions caused despite proper use of drugs prescribed and dispensed by medical institutions and/or pharmacies...

To read the full story

LEXICON

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…